Sanofi and Regeneron's Latest Partnership

Pharmaceutical giant Sanofi (SNY 0.01%) and biotech Regeneron (REGN 0.02%) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (AMGN 0.01%) and Pfizer's (PFE 0.02%) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.